Preview

Кардиология

Расширенный поиск

Формы выпуска и дозы ацетилсалициловой кислоты: значение для клинической практики

https://doi.org/10.18087/cardio.2466

Полный текст:

Аннотация

В статье представлен обзор данных, касающихся фармакокинетики и фармакодинамики различных форм выпуска ацетилсалициловой кислоты (АСК). Показано, что эффективность и безопасность АСК определяется системными эффектами препарата и не зависит от формы выпуска. Обсуждаются вопросы, связанные с резистентностью к АСК.

Об авторе

Е. И. Тарловская
ФГБОУ ВО «ПИМУ» МЗ РФ
Россия


Список литературы

1. Dretzke J., Riley RD, Lordkipanidzé M., Jowett S., O’Donnell J., EnsorJ et al. The prognostic utility of tests of platelet function for the detection of “aspirin resistance” in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technology Assessment. 2015;19 (37):1-366. DOI:10.3310/hta19370

2. Patrignani P., Tacconelli S., Piazuelo E., Di Francesco L., Dovizio M., Sostres C. et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. Journal of Thrombosis and Haemostasis. 2014;12 (8): 1320-30. DOI: 10.1111 /jth. 12637

3. Eikelboom JW, Hirsh J., Spencer FA, Baglin TP, Weitz Л. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012,-141 (2 Suppl): e89S-e119S. DOI: 10.1378/chest. 11-2293

4. Рафальский В. В., Крикова А. В., Багликов А. Н. Особенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препарата. Кардиоваскулярная терапия и профилактика. 2009,8 (7):102-7.

5. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002,324 (7329):71-86. PMID:11786451

6. Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk ofvenous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. Journal of Thrombosis and Haemostasis. 2014,12 (11):1776-87. DOI:10.1111/jth. 12728

7. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002,94 (4):252-66. PMID:11854387

8. Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handbook of Clinical Neurology [Интернет]. Elsevier, 2014 [цитируется по 18 апрель 2018 г.]. с. 577-84. ISBN: 978-0-7020-4086-3

9. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA et al. Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. Cancer Prevention Research. 2012,5 (2):164-78. DOI:10.1158/1940-6207. CAPR-11-0391

10. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004,25 (2):166-81. PMID:14720534

11. Patrono C, Baigent C. Nonsteroidal Anti-Inflammatory Drugs and the Heart. Circulation. 2014,129 (8):907-16. DOI:10.1161/CIRCULA-TIONAHA. 113.004480

12. Bae SK, Seo ОД., Jung EJ, Kim H-S, Yeo C-W, Shon J-H et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography - tandem mass spectrometry: application to pharmacokinetic study of Astrix® in Korean healthy volunteers. Biomedical Chromatography. 2008,22 (6):590-5. DOI:10.1002/bmc. 973

13. Montgomery PR, Sitar DS. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Biopharm Drug Dispos. 1986,7 (1):21-5. PMID:3955197

14. Ali M, McDonald JW, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke. 1980,11 (1):9-13. PMID:7355437

15. Pedersen AK, FitzGerald GA. Dose-Related Kinetics of Aspirin: Pre-systemic Acetylation of Platelet Cyclooxygenase. New England Journal of Medicine. 1984,311 (19):1206-11. DOI:10.1056/NEJM1984 11083111902

16. Levy G. Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol. 1980,10 Suppl 2:285S-290S. PMID:7437270

17. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs. Chest. 2008,133 (6):199S-233S. DOI:10.1378/chest. 08-0672

18. Elwood PC, Morgan G, Galante J, Chia JWK, Dolwani S, Graziano JM, et al. Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. Fukumoto Y, редактор. PLOS ONE. 2016,11 (11):e0166166. DOI:10.1371/jour-nal. pone. 0166166

19. Patrono C. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. Journal of the American College of Cardiology. 2015,66 (1):74-85. DOI:10.1016/j. jacc. 2015.05.012

20. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci. 1982;27 (7):624-35. PMID:6953009

21. Tarnawski A, Stachura J, Gergely H, Hollander D. Gastric microvascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest. 1990;20 (4):432-40. PMID:2121503

22. Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective nonsteroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Dig Liver Dis. 2001;33 Suppl 2: S29-34. PMID:11827360

23. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. BrJ Clin Pharmacol. 1993;35 (3):219-26. PMID:8471398

24. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish J S, Bhatt DL et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. AmJ Cardiol. 2005;95 (10):1218-22. DOI:10.1016/j. amjcard. 2005.01.049

25. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310 (6983):827-30. PMID:7711618

26. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P et al. Primary and Secondary Prevention of Cardiovascular Disease. Chest. 2012;141 (2):e637S-e668S. DOI:10.1378/chest. 11-2306

27. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition ofboth cyclooxygenase 1 and 2. Gastroenterology. 2000;119 (3):706-14. PMID:10982765

28. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40 ( 6):1345-50. PMID:7781458

29. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of National Provider Prescription of PPI Gastroprotection Among Elderly NSAID Users. The AmericanJournal of Gastroenterology. 2008;103 (2):323-32. DOI:10.1111/j. 1572-0241.2007.01595. x

30. Shibata K, Akagi Y, Nozawa N, Shimomura H, Aoyama T. Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction. Journal of Pharmaceutical Health Care and Sciences [Интернет]. 2017 [цитируется по 18 апрель 2018 г.];3 (1). DOI:10.1186/s40780-017-0078-7

31. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361 (9357):573-4. PMID:12598144

32. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64 (4):465-74. PMID:22563589

33. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology. 2017;112 (2):212-39. DOI:10.1038/ajg. 2016.563

34. Chan FKL, Ching JYL, Hung LCT, Wong VWS, Leung VKS, Kung NNS et al. Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. New England Journal of Medicine. 2005;352 (3):238-44. DOI:10.1056/NEJMoa042087

35. Lai K, Chu K, Hui W, Wong BC, Hung W, Loo C et al. Esomeprazole With Aspirin Versus Clopidogrel for Prevention of Recurrent Gastrointestinal Ulcer Complications. Clinical Gastroenterology and Hepatology. 2006;4 (7):860-5. DOI:10.1016/j. cgh. 2006.04.019

36. Writing Committee Members, Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118 ( 18) : 1894-909. D OI: 10.1161 / CIRCU-LATIONAHA. 108.191087

37. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J., Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. The Lancet. 1996,348 (9039):1413-6. DOI:10.1016/S0140-6736 (96) 01254-8

38. Garcia Rodriguez LA, Hernandez-Diaz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. BrJ Clin Pharmacol. 2001,52 (5):563-71. PMID:11736865

39. Kübler W., Darius H. Primäre Prävention der koronaren Herzkrankheit mit Aspirin. Zeitschrift für Kardiologie. 2005,94 (S3):iii66-73. DOI:10.1007/s00392-005-1309-8

40. Patrono C., Rocca B. Aspirin: Promise and Resistance in the New Millennium. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008,28 (3):s25-32.DOI:10.1161/ATVBAHA. 107.160481

41. Аверков О. В. Ацетилсалициловая кислота как антитромбоцитарное средство: какие лекарственные формы препарата предпочтительны с позиций доказательной медицины? Кардиоваскулярная Терапия И. Профилактика. 2010,9 (2):61-8.

42. Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? American HeartJournal. 2004,147 (2):293-300. DOI:10.1016/j. ahj. 2003.07.011

43. Lordkipanidzé M., Diodati JG, Schampaert E., Palisaitis DA, Pharand C. Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease. The American Journal of Cardiology. 2009,104 (9):1189-93. DOI:10.1016/j. amjcard. 2009.06.025

44. Cuisset T., Frere C., Quilici J., Morange P-E, Camoin L., Bali L. et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thrombosis Research. 2009,123 (4):597-603. DOI:10.1016/j. thromres. 2008.04.003

45. Pettersen AA, Arnesen H., Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vascular Pharmacology. 2015,67-69:69. DOI:10.1016/j. vph. 2015.03.018

46. Homorodi N., Kovacs EG, Leé S., Katona É, Shemirani AH, Haramura G., et al. The lack of aspirin resistance in patients with coronary artery disease. Journal of Translational Medicine [Интернет]. 2016 [цитируется по 19 апрель 2018 г.],14 (1). DOI:10.1186/s12967-016-0827-7

47. Di Minno G., Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983,61 (6):1081-5. PMID:6404326

48. Dillinger J-G, Drouet L., Henry P. Letter by Dillinger et al. Regarding Article, “Drug Resistance and Pseudoresistance: An Unintended Consequence ofEnteric Coating Aspirin”. Circulation. 2013,128 (12):e189 -e189. DOI:10.1161/CIRCULATIONAHA. 112.001179

49. Maree AO, Curtin RJ, Dooley M., Conroy RM, Crean P., Cox D., et al. Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. Journal of the American College of Cardiology. 2005,46 (7):1258-63. DOI:10.1016/j. jacc. 2005.06.058

50. Smith JP, Haddad EV, Taylor MB, Oram D., Blakemore D., Chen Q., et al. Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome. Hypertension. 2012,59 (3):719-25. DOI: 10.1161/HYP ERTENSIONAHA. 111.181404

51. Rocca B., Santilli F., Pitocco D., Mucci L., Petrucci G., Vitacolonna E., et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes: Diabetes and variability in aspirin response. Journal of Thrombosis and Haemostasis. 2012,10 (7):1220-30. DOI:10.1111 /j. 1538-7836.2012.04723. x

52. DiChiara J., Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA et al. The Effect ofAspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis From the Aspirin-Induced Platelet Effect (ASPECT) Study. Diabetes. 2007,56 (12):3014-9. D0I:10.2337/db07-0707

53. Evangelista V., De Berardis G., Totani L., Avanzini F., Giorda CB, Brero L., et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. Journal of Thrombosis and Haemostasis. 2007.5 (11):2197-203. D0I:10.1111/j. 1538-7836.2007.02728. x

54. Dragani A., Pascale S., Recchiuti A., Mattoscio D., Lattanzio S., Petruc-ci G. et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythe-mia: implications for antiplatelet therapy. Blood. 2010,115 (5):1054-61. D01:10.1182/blood-2009-08-236679

55. Fiolaki A., Katsanos AH, Kyritsis AP, Papadaki S., Kosmidou M., Mos-chonas IC et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. Journal of the Neurological Sciences. 2017,376:112-6. D0I:10.1016/j. jns. 2017.03.010

56. Rao Z., Zheng H., Wang F., Wang A., Liu L., Dong K. et al. The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. Neurological Research. 2017,39 (8):719-26. D01:10.1080/01616412.2017.1312793

57. Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management: Polycythemia vera and essential thrombocythemia. American Journal of Hematology. 2015,90 (2):162-73. D0I:10.1002/ajh. 23895

58. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Tho-racic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W., Kolh P., Danchin N., Di Mario C. et al. Guidelines on myocardial revascularization. Eur Heart J. 2010,31 (20):2501-55. D0I:10.1093/eurheartj/ehq277

59. Writing Committee Members, Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011,124 (23):e574-651. D. 01:10.1161 / CIR. 0b013 e31823ba622

60. Kovacs EG, Katona É, Bereczky Z., Homorodi N., Balogh L., Toth E., et al. New direct and indirect methods for the detection of cycloox-ygenase 1 acetylation by aspirin, the lack of aspirin resistance among healthy individuals. Thrombosis Research. 2013,131 (4):320-4. D0I:10.1016/j. thromres. 2013.01.033

61. Schwartz ^A, Schwartz DE, Barber K., Reeves M., De Franco A.C. Noncompliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. Journal of Translational Medicine. 2008.6 (1):46. D0I:10.1186/1479-5876-6-46

62. Schwartz ^A, Schwartz DE, Ghosheh K., Reeves MJ, Barber K., DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing ofmyocardial infarction. The American Journal of Cardiology. 2005,95 (8):973-5. D0I:10.1016/j. amjcard. 2004.12.038

63. Bode-Böger SM, Böger RH, Schubert M., FrölichJC. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J. Clin Pharmacol. 1998,54 (9-10):707-14. PMID:9923572

64. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988,2 (8607):349-60. PMID:2899772

65. Lotrionte M., Biasucci LM, Peruzzi M., Frati G., Giordano A., Biondi-Zoccai G. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. Progress in Cardiovascular Diseases. 2016,58 (5):495-504. D0I:10.1016/j. pcad. 2016.02.001


Для цитирования:


Тарловская Е.И. Формы выпуска и дозы ацетилсалициловой кислоты: значение для клинической практики. Кардиология. 2018;58(5S):4-12. https://doi.org/10.18087/cardio.2466

For citation:


Tarlovskaya E.I. Dosage forms and doses of acetylsalicylic acid: significance for clinical practice. Kardiologiia. 2018;58(5S):4-12. (In Russ.) https://doi.org/10.18087/cardio.2466

Просмотров: 71


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)